

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 5 May 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026. The programme is now concluded.

Since the announcement 27 April 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	13,407,992		3,438,931,195
27 April 2026	230,000	260.37	59,884,786
28 April 2026	230,000	263.34	60,567,237
29 April 2026	230,000	260.53	59,921,977
30 April 2026	230,000	264.07	60,735,091
1 May 2026	230,000	274.85	63,216,000
4 May 2026	201,187	282.04	56,743,704
Accumulated under the programme	14,759,179		3,799,999,990

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](https://www.novonordisk.com).

With the transactions stated above, Novo Nordisk owns a total of 32,148,978 B shares of DKK 0.10 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 4 May 2026, Novo Nordisk has since 4 February 2026 repurchased a total 14,759,179 B shares at an average share price of DKK 257.47 per B share equal to a transaction value of DKK 3,799,999,990.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

globalmedia@novonordisk.com

Liz Skrbkova (US)

+1 609 917 0632

lzsk@novonordisk.com

Investors:

Michael Novod

+45 3075 6050

nvno@novonordisk.com

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

Max Ung

+45 3077 6414

mxun@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com

Alex Bruce

+45 34 44 26 13

axe@novonordisk.com

Christoffer Sho Togo Tullin

+45 3079 1471

cftu@novonordisk.com

Frederik Taylor Pitter

+1 609 613 0568

fptr@novonordisk.com

Mads Berner Bruun

+45 3075 2936

mabbz@novonordisk.com